ijtos 2023

International Journal of Trends on OncoScience

Review Article

Immunotherapy for Cancer

Immunotherapy's Promising Potential for Cancer Treatment

Dr. Anand Mohan Jha[1], R. Veerakumar[2], T. Puhazhendhi[3], Kesavan.R[4] and Naveenraj NS[5]

[1] *Post Graduate Department of Chemistry, M. L. S. M. College, Darbhanga (L. N. Mithila University, Darbhanga, Bihar)*

[2] *Department of Pedodontics, Priyadarshini Dental College, Thiruvallur.*

[3] *Department of Public Health Dentistry, Sree Balaji Dental College and Hospital (BIHER University), Pallikaranai, Chennai -100.*

[4] *Dept of Public Health Dentistry,Thai Moogambigai Dental College and Hospital, Chennai.*

[5] *Dept of Public Health Dentistry,JKKN Dental College and Hospital, Namakkal, India*

Abstract: Recent developments in cancer immunology have made it possible to find potential immunotherapies for a variety of malignancies, which has changed the way that cancer is treated. Patients with relapsed or refractory metastatic malignancies have a longer median survival time because of significant research and clinical developments in immunotherapy treatments. The practice of oncology has recently undergone a revolution thanks to immunotherapy for cancer. A significant increase in the variety of innovative immunotherapeutic approaches, including as immune checkpoint suppression, chimeric T-cell antigen receptor treatment, and cancer vaccination, has resulted from using cancer treatment using the immune system. The area of cancer immunotherapy has expanded dramatically since the U.S. FDA authorized the first immune checkpoint inhibitor in 2011. There are several treatment strategies or medications being developed to control various immune system functions. A few of them have shown promising clinical effectiveness, including Vaccines against cancer, adoptive cell therapies (such CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and immune checkpoint inhibitors. For specialized cancer therapies, a number of immunotherapeutic strategies have received approval, and further ones are currently in the stages of clinical and preclinical research Given immunotherapy's success, there has been a major push to increase the clinical effectiveness of the different medicines and techniques used up to now. Here, we review assessment of creation and practical use of numerous immunotherapy techniques now employed cancer treatment. We also discuss the most recent advancements, new patterns, restrictions, and potential benefits of cancer immunotherapy.

Keywords: Immunotherapy, monoclonal antibody, checkpoint inhibitors, Treatment with chimeric antigen receptor (CAR)-T cells, vaccinations, and T cells

***Corresponding Author**

Dr. Anand Mohan Jha , Post Graduate Department of Chemistry, M. L. S. M. College, Darbhanga (L. N. Mithila University,Darbhanga, Bihar)

Received On 26 April, 2023

Revised On 3 May, 2023

Accepted On 19 June, 2023

Published On 10 July, 2023

Funding This research did not receive any specific grant from any funding agencies in the public, commercial or not for profit sectors.

Citation Dr. Anand Mohan Jha, R. Veerakumar, T.Puhazhendhi, Kesavan.R and NaveenRaj NS , Immunotherapy's Promising Potential for Cancer Treatment.(2023).Int. J. Trends in OncoSci.1(3), 25-35

1. INTRODUCTION

Utilizing a patient's immune system to fight cancer, immunotherapy has produced revolutionary treatment strategies and unheard-of clinical results[1]. Despite the fact that immunotherapeutic methods have been effective in a number of cancer subtypes and clinical situations, difficulties still exist [2–5]. To overcome these difficulties, complete understanding of how these treatments work is also necessary [6, 7]. Immunotherapy response can be predicted by specific aspects of tumor-host immune system interactions. Particularly, the tumour microenvironment (TME) influences immune evasion and immunotherapeutic response [8,9]. William Coley's use of living microorganisms as an immunological cancer-fighting stimulant in 1893 gave rise to the idea that the immune system may recognize and restrict tumour growth, however the enthusiasm for cancer immunotherapy has been muted due to inadequate clinical evidence. The immune system's inability to identify and eliminate tumour cells, which allows them to establish themselves in the host, is the cause of this restricted effectiveness [10]. The understanding of how cancer manipulates the immune system and has advanced significantly over the past several decades, which has led to the development of novel strategies to prevent cancer immune evasion in favour of cancer cell elimination. Through the Science Book of the Year, clinical trials have demonstrated their ability to save lives [11]. The success of these treatments also highlights the significance of thorough decoding of fundamental immunology for effective clinical translation in the treatment of cancer. Cancer refers to this dual function of the immune system to either encourage or prevent the growth of cancer immune editing which is divided into three stages: escape, balance, and elimination. The majority of medical oncologists had doubts about the immune system's capacity to detect and destroy cancer during the bulk of the 20th century. The conventional wisdom was that carcinogenesis and disease progression could not occur in the presence of an immune response, and that a cancer diagnosis implied an automatic failure of such antitumor responses. Furthermore, and even now, it has not been conclusively demonstrated that immune responses may prevent the development of clinically apparent illness. Bacillus Calmette-Guerin (BCG), a tuberculosis vaccine preparation made of attenuated Mycobacterium, has recently provided evidence for the link between infections and tumour regressions [12]. BCG can be used to effectively prevent recurrences in most patients with superficial bladder cancer by inducing an antitumor immune response. The molecular processes of immunological system have seen a significant improvement in the recent 25 years of immunological research, which has facilitated the design and development of novel medications and techniques to elicit and control the antitumor immune response both both in vivo and ex vivo. This has enabled a better understanding of the complex interaction between tumor cells and immune cells. New treatments are being developed that target these interactions, improving outcomes for patients with cancer. Through this research, scientists have discovered that cancer cells can evade the immune system by suppressing the body's natural defenses. This new understanding has led to the development of immunotherapies that can help the immune system recognize and attack cancer cells, leading to improved outcomes for cancer patients. This has been a significant breakthrough in cancer treatment, as immunotherapies can be used to target cancer cells specifically, while leaving healthy cells untouched. This offers a more targeted approach to cancer treatment, minimizing damage to healthy cells and reducing side effects.

1.1 Current Cancer Immunotherapy Situation

Among the most promising forms Immune checkpoint inhibitors (ICI) are a component of immunotherapy for cancer. In the previous 10 years, several medications have acquired FDA clearance for more than nine different cancers types [13]. The foundation of ICI treatment is the idea that T cells have evolutionarily conserved negative regulatory signals that function as "checkpoints" to control activation [14]. A short time T cells are activated after increasing the manifestation of inhibitory receptors CTLA4 and PD-1, which subsequently bind to the co-stimulatory ligands B7-1, B7-2, and PD-L1 or PD-L2, respectively[15]. In patients who have previously seen poor results from conventional cancer treatments including radiation and chemotherapy, and targeted therapy, ICI has seen notable success. Durable responses imply that in individuals who react to ICI, long-lasting immunological memory can be observed and formed[16]. This implies that the immune system is capable of recognizing and responding quickly to the same antigen in the future. This makes ICI an attractive option for many diseases, as it could provide long-term protection from the disease with a single dose of the vaccine.

1.2 Vaccines for cancer

By supplying tumor-specific or tumor-associated antigens (TAA) for the immune system to eliminate, cancer vaccines seek to stimulate and enhance pre-existing T-cell and immunological responses [17,18]. Cancer vaccines claim to develop specialised, long-lasting anticancer immunity. It is difficult to create tumor-specific antigens for cancer vaccinations. Antigens are TAAs that are overexpressed or expressed selectively. Nevertheless, in malignancies they are also present in healthy tissues. Targeting TAAs could cause autoimmunity and organ damage due to autoreactive immune reactions[19].Gene mutations connected to cancerous growth give rise to neoantigens. non-human neoantigens present in healthy tissues, may be seen on the surface of the objective cell, recognised T cells produce and are unaffected by tolerance. Recently, the use of next-generation sequencing become more accessible and affordable, which has for the widespread detection and development of several neoantigens[20].Neoantigens have recently been widely identified and established and due to the availability and affordability of next-generation sequencing, there are several potential immune system targets. Neoantigens may be potential inhibitors of oral cancer and may be used to personalize immunotherapy for oral cancer. This allows for the identification of personalized neoantigens that can be used to target the tumor, as well as the development of personalized vaccines that can be used to stimulate the body's immune response against the tumor. This could lead to more effective treatments for oral cancer, as well as a better understanding of the disease and its progression. It could also help to identify individuals at risk for developing oral cancer, allowing for earlier diagnosis and treatment. These personalized neoantigens can be used to create personalized vaccines that are specifically designed to target the unique genetic code of the individual's tumor, which could be more effective than traditional treatments. Additionally, this technology could help to identify individuals at risk for developing oral cancer, allowing for earlier diagnosis and treatment, which could help to improve outcomes and reduce the mortality rate associated with this type of cancer. By

providing this unique form of personalized cancer treatment, not only can we potentially improve survival rates, but it can also help to identify individuals at risk earlier, potentially preventing the progression of the cancer altogether.[64] Sipuleucel-T (Provenge) was the first cancer vaccine given FDA approval for metastatic castration-resistant prostate cancer [21]. The goal is to activate an immune response unique to prostate cancer by targeting prostatic acid phosphatase, an overexpressed TAA[22]. Nucleic acid vaccines also result in a sizable MHC-I-mediated CD8+ T-cell response. Due to their ability to trigger humoral and cellular responses as well as encode full-length tumour antigens, APCs can provide a variety of epitopes. The clinical effectiveness of some DNA vaccines used to treat cervical cancer has been encouraging. Immune stimulants, TAAs, and tumour neoantigens can all be encoded by mRNA vaccines.

1.3 Methods to Improve ICI Therapy

Concentrating on the SDF-1 (CXCR4/CXCL12) signalling pathway may be able to assist ICI get past the TME's physical barrier. In addition to contributing to fibrosis within the tumour and being increased on MDSC/TAMs, CXCR4 is linked to a bad outlook in several cancer types. Combination of anti-PD-L1 drugs with CXCR4 antagonists and overcome ICI opposition[23], liposomal synthesis, polymer-based combinatory techniques, and nano complex technologies were applied. It was possible to create a sustained co-delivery strategy using nanoparticle technology that successfully reprogrammed TAMs to a phenotype similar to the antitumoral M1 and improved their phagocytic skills in a cancer model.[24] Nanotechnology strategies have been explored to promote targeted drug delivery to tumor sites, selectively activating tumor-infiltrating macrophages (TAMs) to improve antitumor immunity. TAMs are capable of exerting both pro- and anti-tumor activities, and repolarization of TAMs from an immunosuppressive to an immunostimulatory phenotype is a promising therapeutic strategy. Nanoparticle-mediated repolarization of TAMs is a potential approach to enhance antitumor immunity[66]. This could reduce the need for booster shots or multiple doses, making it an appealing option for people with limited access to healthcare. It could also make it easier to vaccinate large groups of people, such as during a pandemic. This may prevent the spread of infectious illnesses and saves lives. Additionally, it may lower the price of providing vaccinations, opening up access to a larger spectrum of individuals. These are just a few advantages that might come from this newly developed technology. It may fundamentally alter how we approach immunisation and will have a big influence on world health. The use of vaccines in the battle against infectious illnesses is extremely effective. A healthier and secure world might result from the advancement of this technology by increasing the efficacy and accessible of vaccinations. By utilising this technology, we may speed up the process of developing and distributing vaccines and cut the price of immunisation. People would have easier access to vaccinations as a result, and infectious disease transmission would be curbed. Additionally, this technique might be utilised to develop vaccinations that are more effective, enhancing human health protection. A drop in the global death rate and an improvement in public health would follow from this. Additionally, it could prevent deaths and make the globe safer and healthier. This technology may help lower the cost of vaccinations, lowering healthcare expenses and making it simpler for individuals to get the protection they want. Additionally, as vaccinations would be more widely available and efficient, it may help lower the likelihood of epidemics.

1.4 Methods to Enhance CART Therapy

In treating hematologic malignancies, Efficacy of CART has had significant success. characterised because of effectiveness because of the strong immunosuppressive nature CART trafficking is hampered by the TME, and inhibits tumour growth and activation[25]. To lessen TAM-mediated inhibition of CART growth and function, this drug has been suggested for use as a component of innovative prior to CART, conditioning programmes [26]. Pexidartinib (PLX3397), which inhibits colony-stimulating factor 1 receptor (CSF1R) signalling, improved the effectiveness of adoptive cell transfer in murine melanoma through the inhibition of TAM recruitment and activation [27]. This prevented the suppression of the anti-tumour effect of adoptively transferred CD8+ T cells, leading to improved survival compared to the control group. The results suggest that Pexidartinib could be a promising treatment for melanoma. This increased survival relative to the control group[28] by preventing the inhibition of the anti-tumor impact of adoptively transplanted CD8+ T cells. The outcomes point to Pexidartinib as a potentially effective melanoma therapy. The findings have important ramifications for Pexidartinib's potential as a treatment for melanoma. The clinical effectiveness of Pexidartinib in additional cancer types has to be investigated further. Pexidartinib's effectiveness as a therapy for different forms of cancer is now being investigated in clinical studies. The preliminary findings are encouraging and may result in an exciting new treatment agent for a variety of malignancies. The most recent clinical studies may demonstrate Pexidartinib's potential to be a useful therapeutic option for a number of cancers, and these results call for additional investigation of its efficacy in treating various forms of cancer. To assess Pexidartinib's safety and effectiveness as a possible cancer therapy, more study is required. If effective, Pexidartinib might offer a significant new treatment option for a variety of malignancies. Further investigation of Pexidartinib's ability to treat various tumour types is encouraged by the data that suggests it may be a safe and effective therapy for certain cancers[29].Pexidartinib may offer a useful new treatment option for a range of malignancies, thus it is crucial to continue studying its safety and effectiveness. The effectiveness of Pexidartinib in the treatment of various malignancies has to be confirmed by more study. To assess the drug's effectiveness and safety, clinical studies must be undertaken. Pexidartinib may provide many cancer patients a useful new therapeutic alternative if it is effective.

1.5 Neoantigens used in the cancer vaccine

Compared to self-derived TAA vaccines, neoantigen vaccinations produce a stronger and more focused immune response [30]. Customised The development of clinical recombinant vaccines is a product of the next-generation sequencing (NGS) of cancer DNA [31,32]. Sahin et al. demonstrated that TAAs and neoantigens for vaccines created from NGS elicit strong CD4+ and CD8+ responses. They also demonstrated that patient HLA alleles may be used to detect these substances. Although early neoantigen vaccination studies had encouraging outcomes, there were still some setbacks, and evoking better antitumor responses remains a goal. Further clinical trials are needed to optimize vaccine design and to assess the efficacy of neoantigen vaccines. Additionally, strategies to enhance the body's immune

response to neoantigens need to be developed. Finally, determining the optimal timing and dosing of neoantigen vaccines remains a challenge. Collaborations between academic institutions, pharmaceutical corporations, and regulatory agencies are required to accomplish these aims. Additionally, a careful assessment of the safety of neoantigen vaccinations is required. To develop more potent neoantigen vaccines, it is also necessary to investigate cutting-edge technologies like CRISPR-Cas. Additionally, it is important to do research to determine how to lower the price of making neoantigen vaccines. Collaboration amongst the many stakeholders is required to guarantee the vaccine's affordability, efficacy, and safety. Neoantigen vaccines might be produced more rapidly and precisely because to emerging technologies like CRISPR-Cas[33]. Additionally, research is required to determine how to lower the cost of manufacturing these vaccinations so that they are more widely accessible to the general public. Partnerships between the public and private sectors should be established as well as fair access to the vaccination as part of these efforts. Governments can also offer financial incentives to businesses that invest in vaccine production and research. A In order to create vaccines more cheaply, vaccine producers need also have access to the required technology and raw materials. Governments should also support research to improve the effectiveness of the manufacturing process. The governments should also ensure that intellectual property rules do not prevent the vaccine from being available. To guarantee that the vaccination is accessible to people who need it the most, infrastructure investment in public health should likewise be given top priority.

1.6 Myeloid cells in the cancer microenvironment that suppress the immune system

Tumor-infiltrating lymphocytes, also known as TILs, are poor at removing tumours in vivo, but when the immunosuppressive agent is withdrawn, it may still exert proliferation and effector function tumour microenvironment, are known to exist in developing malignancies. TILs can be used to treat cancer by targeting malignant cells and restoring the immune system's ability to fight cancer. Furthermore, TILs can be used in combination with other therapies to improve the efficacy of cancer treatments. TILs have been used to treat some of the most aggressive forms of cancer, such as melanoma, bladder cancer, and ovarian cancer. Studies have shown promising results when TILs are used in conjunction with other therapies, such as chemotherapy and radiation. The down modulation of processing and presentation of antigens machinery one of the primary strategies used by tumours to elude immune system attack. By encouraging cancer stemness and angiogenesis, tumour cells reprogramme myeloid tissues to both directly promote tumour growth and to provide a setting that suppresses immunity[34]. In this milieu, cancer cells can also withstand medical interventions like chemotherapy and radiation and the immune system. Additionally, this immunosuppressive condition might encourage the formation of brand-new cancer cell clones that are resistant to treatment. This makes the disease more difficult to treat and increases the risk of cancer recurrence and progression. Additionally, in individuals who have received curative therapies, the immunosuppressive condition might raise the likelihood of subsequent tumour development. To lower the risk of recurrence and secondary tumours, it is crucial to consider the immunosuppressive status in cancer patients. To achieve the best results, treatment plans should be customised for each patient. We must find biomarkers that may be utilised to evaluate a patient's immunosuppressive condition in order to do this. These indicators can then be used to direct the selection of the medicines that are most appropriate for each specific patient. The degree of immunosuppression and the likelihood of recurrence, for instance, may be assessed by examining the levels of various cytokines, chemokines, and other immunosuppressive indicators. Additionally, biomarkers can aid in determining which treatments are best for each patient, since too vigorous of a course of treatment may worsen immunosuppression, whilst a less aggressive course of treatment might not be successful. Based on each patient's unique reaction to therapy, doctors can utilise biomarkers to dynamically change treatment approaches. Biomarkers can also be used to detect early signs of oral cancer, such as noticing changes in gene expression or changes in proteins in the saliva. This helps doctors diagnose and treat the cancer in its earliest stages, before it becomes more serious and difficult to treat. This early detection can drastically improve patient outcomes and reduce mortality rates from oral cancer. It can also help reduce the overall cost of treatment since the cancer can be treated earlier and more effectively. Biomarkers provide a reliable and accurate way to diagnose oral cancer at its earliest stages. This allows doctors to catch the cancer before it has a chance to spread and develop into a more serious form. Early detection can also reduce the cost of treatment, as the cancer can be treated more quickly and effectively. Additionally, early detection can drastically improve patient outcomes, as the cancer can be treated before it becomes more difficult to manage[67].

1.7 Adoptive immunotherapy using CAR T cells

Chimeric genes were transduced into T cells by Zelig Eshhar and associates. Expressing single-chain antibodies coupled to an intracellular domain encoding the transmembrane region and the signalling adaptor for the T cell receptor in 1993, which is when AR technology was originally disclosed [35]. The CAR T's capacity cell treatment was proven. In the future, it was shown that human peripheral blood from immune-deficient mice was transduced with CD19 CAR [36]. Studies conducted showed that CAR T cells had the ability to recognize CD19 expressed on the surface of B cells, target them, and kill them, leading to a reduction of tumor burden[37]. This revolutionary treatment has the potential to cure many forms of cancer and has been a major breakthrough in the field of medicine. After transduction, the cells were reinfused into the mice. The mice showed a decrease in tumor burden, demonstrating the therapeutic potential of CAR T cells. The study's findings suggested that CAR T cells may be employed as a successful cancer treatment[38]. This has transformed medicine and offered hope to several cancer sufferers. Clinical trials involving human subjects have confirmed the study's findings, and the FDA has authorised the medicine. Due to the success of CAR T cells, many conditions may now be treated using gene therapy. Gene therapy is now being studied as a potential treatment for conditions including diabetes, Parkinson's, and Alzheimer's. Gene therapy has tremendous potential and might completely change medicine. The outcomes of ongoing clinical studies are highly encouraging. Given that scientists are always coming up with new and creative applications for this technology, gene therapy has a promising future. The possibilities are unlimited as technology develops. Gene therapy corrects damaged or missing genes by injecting genetic material into cells. This can be accomplished through a variety of techniques, including the addition of new

genes, the suppression of existing genes, or even the replacement of absent genes. Researchers have been able to create medicines using this technique for a number of illnesses, such as cancer, cystic fibrosis, and sickle cell anaemia. It's incredibly exciting because gene therapy has the potential to heal many more illnesses, and researchers are actively looking at how to utilise it to treat diseases like Alzheimer's, Parkinson's, and diabetes. Scientists can modify a cell's genetic composition to increase its resistance to sickness or its capacity to fend off infection. This can be accomplished by adding new genetic material, silencing already present genes, or adding missing genes. There is potential for much greater advancement in the future, and this technology has already had a significant influence on the treatment of numerous diseases. In the not too distant future, gene editing may be utilised to cure everything from heart disease to cancer. It has the potential to transform medical practise and may potentially result in the discovery of novel remedies for diseases that were formerly thought to be incurable.

1.8 Neoantigens from tumours and therapeutic cancer vaccinations

Despite the great clinical results that immune checkpoint inhibition and CAR treatments were able to accomplish, overall results were excellent since the main therapeutic benefit for cancer patients was extended survival. since these antigens do not produce T lymphocytes eliminated via central tolerability systems, neoantigens that result from There have been tumor-specific mutations. proposed to be of special significance to the prevention of cancer following vaccination [39]. These neoantigens have the potential to induce a strong immune response, and could be used to target tumor cells. Vaccines using tumor-specific neoantigens could be used to reduce the risk of developing cancer in individuals with genetic predisposition. By inducing a targeted immunological reaction against neoantigens, such vaccines may potentially be utilised to treat already-existing tumours. This could enhance the prognosis for cancer patients. Clinical studies have been conducted on this strategy, and some patients showed encouraging outcomes. Larger trials are required to prove its efficacy and safety, though. The identification of neoantigens that are expressed in tumours but not in healthy cells is a significant hurdle in cancer immunotherapy. For this, accurate sequencing of tumour and healthy tissue samples is necessary. More potent methods for triggering an immune response to neoantigens also need to be developed. To activate an immune response to the neoantigens, current techniques include vaccinations. Unfortunately, these methods frequently have poor safety and effectiveness profiles. Scaling up these therapies to bigger populations is also challenging due to the high cost and lengthy development of personalised vaccines[40]. Alternative strategies are thus required to safely and cost-effectively target neoantigens. The use of immunotherapies or gene treatments that can efficiently target neoantigens without causing harmful side effects may fall under this category. At the moment, the expense and complexity of mass-producing personalised vaccinations are their main drawbacks. This sparked investigation into complementary medicines that can more successfully and affordably target neoantigens. Such treatments would be able to precisely target neoantigens and lower the possibility of harmful side effects. These neoantigens are capable of stimulating the adaptive immune system to produce T lymphocytes, which in turn are able to recognize and kill tumor cells[41]. This suggests that neoantigens are a promising target for cancer vaccines that could potentially induce tumor-specific immunity and provide long-term protection from cancer.

1.9 vaccines for cancer

Successful therapeutic cancer vaccines stimulate the cancer patients' immune systems, eradicating or permanently controlling the illness. Such a vaccination often contains a tumour antigen in an immunogenic formulation and activates helper cells, CTLs, and/or B cells that are specific for the tumour antigen. To lyse or phagocytose cells which exhibit antigens they recognize, B cells produce their unique antibody receptors. Small cell-derived peptides displayed on a cell's surface linked to Class I MHC molecules are particularly recognized by CTLs via their TCR, or T cell receptor. T cell will release cytotoxic chemicals and cytokines that will destroy the cell and prompt the turning on of neighbouring immune cells if it is activated and its TCR binds a certain MHC/peptide combination in Figure 1. Preventive vaccination against the human papilloma virus (HPV) has shown to be the most effective cancer vaccine strategy to date.



Fig 1: Generation of antitumor T cell responses using cancer vaccines and immune stimulatory agents[42]

Up to 70% of cervical cancers and other malignancies linked to HPV infection might potentially be avoided via HPV vaccination. The vaccination works by boosting the immune system of the body, activating T cells, and preparing them to identify and combat the virus if it is ever met. A powerful weapon for preserving the public's health is vaccination. Given that the HPV virus may spread through sex, it is advised that both children and adults get the vaccination. The best method of defence against HPV and the malignancies it is related with is vaccination. The only means of preventing HPV infection and the illnesses it is linked to is vaccination. It's crucial to get immunised before engaging in sexual activity. Vaccines are widely accessible in a lot of international locations. Vaccinations are secure and reliable. Health care providers offer vaccinations for no cost or at a minimal cost. Additionally, the majority of pharmacies carry vaccines. As they confer immunity from the virus before it is infected, vaccinations are the most reliable method of preventing HPV and the malignancies it is associated with. They have also received approval from the world's top medical organisations and are safe, effective, and free of any harmful side effects. Additionally, vaccinations are widely accessible to everyone in many nations because to their low cost or availability for free.

1.10 CD40 Opponents

For complete activation and efficient brand-new T cells priming, the CD40 cell surface receptor on DCs must be ligated. When CD4+ T helper cells are generated when antigen recognition, the natural ligand CD40L is increased, and this expression causes the APC to become even more active. Using a number of established methods, CD40 signalling can support antitumor immune activity. encouraging macrophage activity by triggering the generation of microbicidal compounds such nitric oxide as well as reactive oxygen species; CD40 signalling can also increase the production of cytokines by macrophages, such as interleukin-12, which can help to activate T-cells and increase the production of antibodies that can help to target and destroy tumor cells[43]. Additionally, CD40 signalling can boost the synthesis of chemokines, which can attract additional immune cells to the tumour site and aid in the removal of the tumour. In addition, co-stimulatory molecule production on antigen-presenting cells may be increased as a result of CD40 signalling, which may aid in further activating T cells. The subsequent activation of T-cells can aid in the direct destruction of tumour cells as well as trigger an immune cell response that is anti-tumor. Additionally, CD40 signalling aids in the activation of natural killer cells, which can aid in the continued destruction of tumour cells. It can also boost the production of cytokines, which can aid in triggering a powerful immune response to fight the tumour. This immune response can aid in the destruction of tumour cells and offer ongoing defence against the return of cancer. This is due to the fact that CD40 signalling aids in activating T-cells and natural killer cells, which may directly target and eradicate cancer cells as well as emit cytokines that aid in promoting an efficient immune response against the tumour. This aids in generating a potent and durable anti-tumor response that can assist to fend off tumour recurrence in the future.

1.11 Transfer of Adoptive T Cells

Those that have metastatic stage III and stage IV melanoma now have a potent therapeutic option thanks to immunotherapy employing T cells. T cell immunotherapy involves the adoptive transfer of autologous tumour infiltrating lymphocytes (TILs) along with high-dose IL-2 [44,45]. TILs and high-dose IL-2 have longest clinical history, with many clinical studies conducted at facilities throughout the world consistently demonstrating durable clinical response rates of close to 50% or more in patients who have failed first- and

second-line treatment modalities [46–50] These studies have also shown that TILs and high-dose IL-2 have fewer side effects than other therapies, making them a viable option for patients who have already tried other treatments. In addition, they have been found to be cost-effective.



Fig 2: Adoptive T cell therapy for metastatic melanoma[51].

1.12 Antibody Checkpoints

Exogenous immunogens or endogenous immunogens generated by mutated or remodelled cells present a constant threat immunity system. The effector elements immunological system continually strives to remove the foreign and endogenous immunogens' causal agents and preserve immunological homeostasis. Immune tolerance, a form of feedback regulation, guards against collateral harm brought on by an overly active immune response. immunological an example of a group of molecular immunological tolerance effectors that keep the defence mechanism of equilibrium and prevent autoimmunity [52,53]. The checkpoint proteins interact with their corresponding ligands to enable immune cells discriminate between self and non-self. They and shown on the surface of immune cells. By expressing the ligands of immunological checkpoints, tumour cells may utilise this homeostatic mechanism through immune editing. These immunological checkpoints are essential for fighting cancer. By controlling these checkpoints, tumour cells can evade the immune system and survive. Consequently, immunotherapy has been developed to target these checkpoints and reactivate the anti-tumour immunity.

1.13 For cell therapy Adoption

Another quickly developing area of immunotherapy for cancer is adoptive cell therapy (ACT), in which a patient's cells are genetically modified & in vivo then returned to the patient's body as therapeutic agents. TILs (tumor-infiltrating lymphocytes), Synthetic TCRs (engineered T-cell receptors), CAR T (chimeric T cells with an antigen receptor), and CAR-NK, which uses the NK cells examples of T cell-based adoptive cell therapy. Since its inception, ACTs have advanced significantly; as of 2022, around 2756 active cell treatments are in different phases of research. In the worldwide oncology market, there are more than 2500 estimated active cell therapy molecules, and CAR-T therapies continue to dominate the cell-based treatment pipeline [54].

1.14 Molecular antibodies

A class of potential targeted anticancer therapies Monoclonal antibodies (mAbs) have a range of mechanisms of action. Piperine, a natural alkaloid present in black pepper, has been reported to possess anticancer properties in Oral cancer. It has been shown to induce apoptosis, inhibit cell proliferation, and modulate the expression of cell cycle-related proteins. Piperine has also been found to downregulate the expression of NF-κB, p53, and Bcl-2 proteins, which are involved in the regulation of apoptosis and cell proliferation. In addition, piperine has been shown to reduce the activation of the inflammatory cytokines TNF-α, IL-1β, and IL-6. This suggests that piperine has the potential to act as an anti-tumor agent, as it can induce apoptosis and inhibit cell proliferation. Furthermore, its ability to reduce the activation of inflammatory cytokines suggests that it could have anti-inflammatory properties as well [68]. Since the successful use of immunoglobulin G (IgG) mAbs, significant advancements in antibody engineering technology have resulted in the creation of newer and more effective antibody formats and derivatives, including antibody fragments, non-IgG scaffold proteins, bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), antibody-radio conjugates, and immunocytokines. These have all been used in turn as alternative therapeutic agents for a variety of diseases. Figure 4A shows the different

methods that monoclonal antibodies assault cancer cells, including direct targeting killing and immune-mediated damage, immunological checkpoint blocking, stopping blood vessel development, and medication delivery cancerous cells [55] Cancers such as breast, lung, ovarian, and colorectal have all been treated using monoclonal antibodies. They have also been used to treat autoimmune conditions like psoriasis, multiple sclerosis, and rheumatoid arthritis. Other disorders including Alzheimer's, heart disease, and HIV/AIDS are also being treated with monoclonal antibodies. They are also being studied as a potential therapy for contagious illnesses including the flu and malaria. The potential application of monoclonal antibodies in various fields, such as gene therapy, is being researched. Due to their ability to attach to certain molecules in the body, they may also be helpful in the diagnosis of disorders. Biosensors are used in the field of early diagnosis, as they are capable of providing real-time information about the body's internal environment. They are used to detect the presence of certain molecules in the body, allowing for early diagnosis and treatment of diseases. Biosensors are also used to monitor the effectiveness of treatments, as well as to detect changes in the body over time. They can also be used to measure the concentrations of various substances in the body, such as glucose levels in diabetics. Biosensors have the added advantage of being non-invasive, meaning they can be used to measure substances without the need for blood or other bodily fluids. Additionally, biosensors are highly sensitive and can detect changes in the body in real-time, allowing for more accurate and timely diagnosis and treatment of diseases. Biosensors can also provide continuous monitoring, helping to diagnose and treat diseases quickly and effectively[65]. The use of monoclonal antibodies in immunotherapy, which improves the body's capacity to detect and combat illness, is another possible use. Additionally, they can be utilized to administer medications specifically to particular organs or tissues. Additionally, cancer cells can be found using monoclonal antibodies, enabling early detection and treatment.

1.15 Drug-Antibody Conjugates

The monoclonal antibody-based cancer immunotherapy field that is growing most quickly is ADCs[56]. Compared to only antibodies, they are far more efficient. This approach involves a chemical linker that is aimed against a target cell surface antigen expressed on cancer cells connecting the lethal payload to the lethal mAb. The monoclonal antibody (mAb), the linker, and the cytotoxic or cytostatic/cytotoxic chemical are the usual components of an ADC. By binding to tumour antigens, a crucial element of ADC that determines specificity to the cancer cell, the mAb acts as a precise carrier to deliver the cytotoxic chemicals to the target cell without damaging healthy cells that do not express the target antigen. As a result of the complexity of its various components, ADCs demand extensive research. The selection of an appropriate target, the specificity of the mAb, the cytotoxic payload, and the technique utilised to bind the antibody to the payload are crucial variables that may impact the safety and effectiveness of ADCs. For the treatment of metastatic and unreliable HER-2 low breast cancer in 2022, the FDA recently approved the use of fam-trastuzumab deruxtecan-nxki, an anti-HER2 ADC (Enhertu, Daiichi Sankyo, Inc.). Enhertu is the first specific therapy for breast tumours of the HER-2 low subtype[57]. The previously challenging-to-treat patients with HER-2 low breast cancer will now have a much-needed therapy alternative. It is anticipated that it will decrease mortality and enhance patient outcomes. Clinical trials have demonstrated that the medication is both safe and effective, with little adverse effects. The FDA must still approve the medicine before it can be sold to the general public. Many medical professionals and patients are eagerly awaiting its release, which is anticipated to happen within the upcoming few months. The drug's producer is also aiming to lower the cost of the medication for all patients. The medication has the potential to change the face of medicine and potentially save many people's lives. It is hoped that the medication will be widely accessible in the near future so that anybody who need it can take advantage of its effects.

1.16 Cytokine Treatments

Even despite the creation the immune system's cytokines are crucial to the cancer immunity cycle, and malignancies have dysregulated activity of numerous cytokines [58,59]. IL-2 was the first cytokine employed in the treatment of cancer. It is acknowledged as the first human cancer immunotherapy that is reproducible and successful, as well as the first cytokine treatment. Despite promising preclinical findings, no further cytokines or cytokine antagonists have shown promise as monotherapies in patients with advanced-stage cancer. Nevertheless, the FDA authorised PEG-interferon-2b (PEG-IFN) and interferon-alpha as adjuvant treatments for resected stage III melanomas[60]. To ascertain if these therapies are effective, larger clinical studies are required. Future treatment alternatives might be provided by medications that target cytokines and cytokine receptors. To completely comprehend the function of cytokines in the therapy of cancer, more investigation is necessary. This includes the development of newer congeners of doxycycline that could be used to target specific cytokines and their receptors, as well as a better understanding of the complex interactions between cytokines and cancer cells. Additionally, the study of cytokine-based therapies should focus on identifying biomarkers that can be used to predict the efficacy of such therapies. More research is also needed to determine the optimal dosage and delivery method of cytokines for cancer treatment. This could lead to more precise treatments with fewer side effects and improved outcomes. It could also help to identify which patients may benefit the most from cytokine-based therapies and which ones may not respond to such treatments at all. In addition, the research may provide insight into how cytokines can be used in combination with other therapies to effectively treat cancer[69]. Studies are being conducted to evaluate the efficacy and safety of these therapies. The most effective forms of cancer treatment continue to be other procedures like radiation and chemotherapy. The ideal method for treating cancer will require further investigation. To enhance results and reduce adverse effects, new therapies and delivery strategies are being researched. Doctors, researchers, and patients will need to work together to create novel therapies and enhance existing ones. To verify their safety and effectiveness, new therapies and procedures must be tried out and assessed. To make sure that patients' needs are satisfied and that their opinions are heard in this process, patient advocacy groups play a crucial role. We can advance the battle against cancer by cooperating.

1.17 Viral oncolytic agents

Oncolytic viruses (OVs) are virulent-reduced genetically modified viruses with the capacity to target and kill cancer cells while causing no damage to normal cells [61] Cancer cell death induction and an increase in both innate and tumor-specific adaptive immune responses are two crucial properties of OVs,

a novel class of pharmaceuticals [62]. Two alternative mechanisms exist for oncolytic viruses to destroy cancer cells: directly through virus-mediated cytotoxicity and indirectly through cytotoxic immune effector pathways. Additionally, OVs have the ability to enlist and stimulate the immune system to target tumour cells, boosting antitumor immunity and improving patient outcomes. Additionally, OVs can lessen the immunosuppressive milieu of tumours, which can improve their effectiveness as anticancer medications. OVs have the potential to completely change how cancer and other illnesses are treated. They may have fewer negative effects than conventional medicines and can be designed to target certain diseases[63]. OVs can also be used in conjunction with other treatments to increase their efficacy. OVs are being developed for use in a variety of disorders and have already demonstrated their efficacy in clinical studies. They provide a promising future research direction because of their potential to revolutionise cancer treatment. A lot of people who would not have access to conventional therapies may find that OVs are a feasible alternative because to their affordability and ability to be manufactured rapidly and affordably. Additionally, since OVs may be customised for each patient, therapies can be better adapted. Many people find OVs to be a desirable alternative because they have been demonstrated to be safe and have little negative effects. With more study, OVs may soon play a significant role in the therapy of cancer and may completely alter how illnesses are managed. Cancers have been treated using OVs, which have been demonstrated to be successful at locating and eliminating cancer cells while sparing healthy cells. Additionally, OVs may be modified to target certain molecules and pathways, enabling more specialised and individualised therapies. OVs have been used to deliver bio-based materials for chronic diabetic care, and as a way to deliver gene therapies or stem cells for treating cancer, cardiovascular diseases, and neurological disorders. OVs have a large surface area that can be modified to bind to specific molecules and pathways, making them highly versatile and adaptable to a variety of treatments. They can also be used to deliver specific materials directly to the site of the disease, which can help to reduce side effects and increase the effectiveness of the treatment. OVs have been used in a range of treatments, from cancer to HIV, and they are continuing to be explored for more applications. OVs are also attractive as they can be tailored to deliver different types of molecules, making them a promising tool for drug delivery[70]. Due to the fact that they may be customised to each patient's needs while having few side effects, they are a desirable alternative for patients.

2. CONCLUSION

Many solid and hematologic cancers are now treated quite differently because to cancer immunotherapies like ICIs and CAR-T. Expanding the indications for already existing medicines and finding new methods to use the immune system to treat cancer are two ongoing research topics. Immunotherapies have revolutionized the way that solid and hematologic malignancies are treated, yet because of how they work, they have different toxicity profiles. Numerous clinical trials are being conducted to evaluate ICI's safety and effectiveness when used with cutting-edge immunomodulatory medications and targeted molecular therapies for conventional cancer treatment. To learn how to avoid antigen escape and choose highly immunogenic tumor-specific antigens that elicit a powerful antitumor immune response while reducing toxicity profile, further research is required in CAR-T cell-based treatments, particularly for solid tumours.

3. AUTHORS CONTRIBUTION STATEMENT

Dr. Anand Mohan Jha and R. Veerakumar conceptualized and gathered the data about this work. T. Puhazhendhi, Kesavan.R and Naveenraj NS contributed to this manuscript's writing and design.

4. CONFLICT OF INTEREST

Conflict of interest declared none.

5. REFERENCES

1. Gonzales Carazas, M.M.; Pinto, J.A.; Casado, F.L. Biological bases of cancer immunotherapy. Expert Rev. Mol. Med. 2021, 23, e3.
2. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.;Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454
3. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639.
4. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.;Plimack, E.R.; et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015, 373, 1803–1813.
5. Beckermann, K.E.; Dudzinski, S.O.; Rathmell, J.C. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017, 35, 7–14.
6. Wang, S.; Xie, K.; Liu, T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms—Not Only Checkpoint Matters. Front. Immunol. 2021, 12, 690112
7. Lagos, G.G.; Izar, B.; Rizvi, N.A. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. Am. Soc. Clin. Oncol. Educ. Book 2020, 40, e47–e57. [
8. Zhou, C.; Liu, Q.; Xiang, Y.; Gou, X.; Li,W. Role of the tumor immune microenvironment in tumor immunotherapy (Review). Oncol. Lett. 2021, 23, 53
9. Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat.Rev. Immunol. 2020, 20, 651–668.
10. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. *Adv Immunol*. 2006;90:51–81.
11. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. *Science*.2013;342(6165):1432–1433.
12. Schreiber RD, Old LJ, Smyth MJ. Cancer immune editing: integrating immunity's roles in cancer suppression and promotion. *Science*.2011;331(6024):1565–1570.

13. Dobosz, P.; Dzieciatkowski, T. The Intriguing History of Cancer Immunotherapy. Front. Immunol. 2019, 10, 2965
14. Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat.Rev. Immunol. 2020, 20, 651–668
15. Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and personalized medicine. 2014 Nov 15:357-65.
16. Goggi JL, Khanapur S, Hartimath SV, Ramasamy B, Cheng P, Chin HX, Tang JR, Hwang YY, Robins EG. Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon Cancer. Biomedicines. 2022 Sep 20;10(10):2343.
17. Shetty, K.; Ott, P.A. Personal Neoantigen Vaccines for the Treatment of Cancer. Annu. Rev. Cancer Biol. 2021, 5, 259–276
18. Zhang, Z.; Lu, M.; Qin, Y.; Gao, W.; Tao, L.; Su, W.; Zhong, J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front.Immunol. 2021, 12, 672356
19. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood, The Journal of the American Society of Hematology. 2011 Jul 21;118(3):499-509.
20. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. 2019:9-30.
21. Wei, X.X.; Perry, J.; Chang, E.; Zhang, L.; Hiatt, R.A.; Ryan, C.J.; Small, E.J.; Fong, L. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Sipuleucel-T Immunotherapy. Clin. Genitourin.Cancer 2018, 16, 184–190.e2.
22. Higano, C.S.; Schellhammer, P.F.; Small, E.J.; Burch, P.A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115, 3670–3679
23. Li, Z.;Wang, Y.; Shen, Y.; Qian, C.; Oupicky, D.; Sun, M. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci. Adv. 2020, 6, eaaz9240
24. Ramesh, A.; Malik, V.; Ranjani, H.A.; Smith, H.; Kulkarni, A.A. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy. Drug Deliv. Transl. Res. 2021, 11, 2317–2327
25. Murad, J.P.; Tilakawardane, D.; Park, A.K.; Lopez, L.S.; Young, C.A.; Gibson, J.; Yamaguchi, Y.; Lee, H.J.; Kennewick, K.T.; Gittins, B.J.; et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol. Ther. 2021, 29, 2335–2349.
26. Nywening, T.M.;Wang-Gillam, A.; Sanford, D.E.; Belt, B.A.; Panni, R.Z.; Cusworth, B.M.; Toriola, A.T.; Nieman, R.K.;Worley, L.A.; Yano, M.; et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients
27. with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-aniel, dose-finding, non-randomised, phase 1b trial. Lancet. Oncol. 2016, 17, 651–662.
28. Cheng L, Du X, Wang Z, Ju J, Jia M, Huang Q, Xing Q, Xu M, Tan Y, Liu M, Du P. Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. Journal of hepatology. 2014 Dec 1;61(6):1297-303.
29. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature reviews Drug discovery. 2018 Dec;17(12):887-904.
30. Mok, S.; Koya, R.C.; Tsui, C.; Xu, J.; Robert, L.;Wu, L.; Graeber, T.;West, B.L.; Bollag, G.; Ribas, A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014, 74, 153–161.
31. Shetty, K.; Ott, P.A. Personal Neoantigen Vaccines for the Treatment of Cancer. Annu. Rev. Cancer Biol. 2021, 5, 259–276.
32. Yadav, M.; Jhunjhunwala, S.; Phung, Q.T.; Lupardus, P.; Tanguay, J.; Bumbaca, S.; Franci, C.; Cheung, T.K.; Fritsche, J.;Weinschenk, T.; et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515, 572–576.
33. Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MW, Mani P, Rao TN, Sekar D. CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer. 2022 Mar 24;21(1):83.
34. Adalsteinsson, V.A.; Ha, G.; Freeman, S.S.; Choudhury, A.D.; Stover, D.G.; Parsons, H.A.; Gydush, G.; Reed, S.C.; Rotem, D.; Rhoades, J.; et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 2017, 8, 1324
35. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *J Clin Invest*.2015;125(9):3365–3376.
36. Eshhar Z, Waks T, Gross G, Schindler DG.Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A*. 1993;90(2):720–724.
37. Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu YU, Tu S, Li Y. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Frontiers in immunology. 2019 Nov 12;10:2664.
38. Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. The Lancet Oncology. 2020 Mar 1;21(3):e168-78
39. Brentjens RJ, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.*Nat Med*. 2003;9(3):279–286
40. Kesik-Brodacka M. Progress in biopharmaceutical development. Biotechnology and applied biochemistry. 2018 May;65(3):306-22.
41. Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell–based treatments for solid tumors. Nature medicine. 2019 Oct;25(10):1488-99.
42. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science*. 2015;348(6230):69–74.
43. Bose A, Baral R. Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf

preparation is associated with CD40–CD40L–mediated endogenous production of interleukin-12. Human immunology. 2007 Oct 1;68(10):823-31.
44. Future II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N. Engl. J. Med.* 356:1915–27
45. Dudley ME, Wunderlich JR, Robbins PF, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 298:850–54
46. Rosenberg SA, Yang JC, Sherry RM, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* 17:4550–57
47. Dudley ME, Gross CA, Langhan MM, et al. 2010. CD8+ enriched "young" tumor infiltrating lymphocytescan mediate regression of metastatic melanoma. *Clin. Cancer Res.* 16:6122–31
48. Dudley ME, Wunderlich JR, Yang JC, et al. 2005. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J. Clin. Oncol.* 23:2346–57
49. Dudley ME, Yang JC, Sherry R, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma:evaluation of intensive myeloablative chemoradiation preparative regimens. *J. Clin. Oncol.* 26:5233–39
50. Besser MJ, Shapira-Frommer R, Treves AJ, et al. 2010. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. *Clin. Cancer Res.* 16:2646–55
51. Radvanyi LG, Bernatchez C, Zhang M, et al. 2010. Adoptive T-cell therapy for metastatic melanoma:The MD Anderson experience. *J. Immunother.* 33:863
52. Yvon E, Del Vecchio M, Savoldo B, et al. 2009. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. *Clin. Cancer Res.* 15:5852–60
53. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6, 715–727.
54. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137–148.
55. Saez-Ibañez, A.R.; Upadhaya, S.; Partridge, T.; Shah, M.; Correa, D.; Campbell, J. Landscape of cancer cell therapies: Trends and real-world data. Nat. Rev. Drug Discov. 2022
56. Taylor, R.P.; Lindorfer, M.A. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol. 2016, 28, 309–316
57. Siddiqui T, Rani P, Ashraf T, Ellahi A. Enhertu (Fam-trastuzumab-deruxtecan-nxki)–Revolutionizing treatment paradigm for HER2-Low breast cancer. Annals of Medicine and Surgery. 2022 Oct;82.
58. Bornstein, G.G. Antibody Drug Conjugates: Preclinical Considerations. AAPS J. 2015, 17, 525–534.
59. Chulpanova, D.S.; Kitaeva, K.V.; Green, A.R.; Rizvanov, A.A.; Solovyeva, V.V. Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. Front. Cell Dev. Biol. 2022, 8, 402
60. D'Aniello C, Perri F, Scarpati GD, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M. Melanoma adjuvant treatment: current insight and clinical features. Current Cancer Drug Targets. 2018 Jun 1;18(5):442-56.
61. Qiu, Y.; Su, M.; Liu, L.; Tang, Y.; Pan, Y.; Sun, J. Clinical application of cytokines in cancer immunotherapy. Drug Des. Devel. Ther. 2021, 15, 2269–2287.
62. Zheng, M.; Huang, J.; Tong, A.; Yang, H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances. Mol. Ther.
Oncolytics 2019, 15, 234–247.
63. Łobocka M, Dąbrowska K, Górski A. Engineered bacteriophage therapeutics: rationale, challenges and future. BioDrugs. 2021 May;35(3):255-80.
64. Natarajan PM, Umapathy VR, Murali A, Swamikannu B. Computational simulations of identified marine-derived natural bioactive compounds as potential inhibitors of oral cancer. Future Sci OA, published online on 2022. 2022;8(3):FSO782. doi: 10.2144/fsoa-2021-0148, PMID 35251696.
65. Umapathy VR, Natarajan PM, Swamikannu B, Moses J, Jones S, Chandran MP et al. Emerging Biosensors for Oral Cancer Detection and Diagnosis-A Review Unravelling Their Role in Past and Present Advancements in the Field of Early Diagnosis. Biosensors. 2022;12(7):498. doi: 10.3390/bios12070498, PMID 35884301.
66. Umapathy VR, Natarajan PM, SumathiJones C, Swamikannu B, Johnson WMS, Alagarsamy V et al. Current trends and future perspectives on dental nanomaterials – an overview of nanotechnology strategies in dentistry. J King Saud Univ Sci. 2022;34(7):102231. doi: 10.1016/j.jksus.2022.102231.
67. Umapathy VR, Natarajan PM, Swamikannu B. Comprehensive review on development of early diagnostics on oral cancer with a special focus on biomarkers. Appl Sci. 2022;12(10):4926. doi: 10.3390/app12104926.
68. Rekha U V, Mn P, S B. Review on Anticancer properties of piperine in Oral cancer: therapeutic Perspectives. Res J Pharm Technol. 2022;15(7):3338-42. doi: 10.52711/0974-360X.2022.00558.
69. Natarajan P, Rekha V, Murali A, Swamikannu B. Newer congeners of doxycycline – do they hold promise for periodontal therapy?. amscd. 2022;7(1):16-23. doi: 10.5114/amscd.2022.119600.
70. Pei J, Palanisamy CP, Alugoju P, Anthikapalli NVA, Natarajan PM, Umapathy VR et al. A comprehensive review on bio-based materials for chronic diabetic wounds. Molecules. 2023;28(2):604. doi: 10.3390/molecules28020604, PMID 36677658.